| Name | 1-[(2R)-4-[5-[(4-fluorophenyl)methyl]thiophen-2-yl]but-3-yn-2-yl]-1-hydroxyurea |
|---|---|
| Synonyms |
[14C]-Atreleuton
(R)-N-(3-(5-(4-fluorophenylmethyl)-2-thienyl)-1-methyl-2-propynyl)-N-hydroxyurea Atreleuton [USAN] Atreleuton ABT-761 Atreleuton (USAN/INN) UNII-U301T88E1M (R)-N-{3-[5-(4-fluorophenylmethyl)-thien-2-yl]-1-methyl-2-propynyl}-N-hydroxyurea |
| Description | Atreleuton (ABT-761) is a selective, reversible, and orally bioavailable 5-Lipoxygenase (5-LO) inhibitor. Atreleuton (ABT-761) exhibits potent and selective inhibition of leukotriene formation[1][2][3]. |
|---|---|
| Related Catalog | |
| Target |
5-LO[1] |
| References |
[2]. Reid JJ, et al. ABT-761 (Abbott). Curr Opin Investig Drugs. 2001 Jan;2(1):68-71. |
| Density | 1.37g/cm3 |
|---|---|
| Boiling Point | 506.7ºC at 760mmHg |
| Molecular Formula | C16H15FN2O2S |
| Molecular Weight | 318.36600 |
| Flash Point | 260.2ºC |
| Exact Mass | 318.08400 |
| PSA | 95.79000 |
| LogP | 3.50170 |
| Vapour Pressure | 4.34E-11mmHg at 25°C |
| Index of Refraction | 1.652 |
| Symbol |
GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H302 |
| Hazard Codes | Xi |
| RIDADR | NONH for all modes of transport |
|
~17%
154355-76-7 |
| Literature: Brooks; Stewart; Basha; Bhatia; Ratajczyk; Martin; Craig; Kolasa; Bouska; Lanni; Harris; Malo; Carter; Bell Journal of Medicinal Chemistry, 1995 , vol. 38, # 24 p. 4768 - 4775 |
|
~%
154355-76-7 |
| Literature: Brooks; Stewart; Basha; Bhatia; Ratajczyk; Martin; Craig; Kolasa; Bouska; Lanni; Harris; Malo; Carter; Bell Journal of Medicinal Chemistry, 1995 , vol. 38, # 24 p. 4768 - 4775 |
|
~%
154355-76-7 |
| Literature: Brooks; Stewart; Basha; Bhatia; Ratajczyk; Martin; Craig; Kolasa; Bouska; Lanni; Harris; Malo; Carter; Bell Journal of Medicinal Chemistry, 1995 , vol. 38, # 24 p. 4768 - 4775 |